

AWARD NUMBER: W81XWH-14-1-0535

TITLE: Cooperativity Between Oncogenic PKC Epsilon and Pten Loss in Prostate Cancer Progression

PRINCIPAL INVESTIGATOR: Marcelo G. Kazanietz, Ph.D.

CONTRACTING ORGANIZATION: Trustees of the University of Pennsylvania
Philadelphia, PA 19104

REPORT DATE: October 2016

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2016		2. REPORT TYPE Annual report		3. DATES COVERED 30 Sep 2015 - 29 Sep 2016	
4. TITLE AND SUBTITLE Cooperativity Between Oncogenic PKC Epsilon and Pten Loss in Prostate Cancer Progression				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-14-1-0535	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Marcelo G. Kazanietz, Ph.D. E-Mail: marcelog@upenn.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Trustees of the University of Pennsylvania Philadelphia, PA 19104				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S) USAMRMC	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The main objective of our studies is to elucidate the mechanisms by which PKCε, in conjunction with Pten loss, lead to malignant transformation and metastasis, through an autocrine mechanism that involves the release of the chemokine CXCL13. During the first year we acquired new evidence that CXCL13 levels are elevated in prostate cancer cells and that PKCε is causally associated with the elevated production and release of this chemokine. We also initiated studies to dissect the signaling mechanisms that mediate CXCL13 induction. We took advantage of a cellular model that we generated in our laboratory in which PKCε was overexpressed using a lentivirus in a Pten-deficient background. We also remediated the issue of loss of stable PKCε expression in prostate epithelial cell lines by generating a new PKCε lentivirus. Our research may impact on our understanding of the molecular mechanisms of prostate tumorigenesis, and may have significant prognostic and therapeutic implications.					
15. SUBJECT TERMS PKCε, Pten, CXCL13, CXCR5, proliferation, migration, tumorigenesis, metastasis, CXCL13 promoter, transcriptional activation, autocrine loop, mouse models.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
Unclassified	Unclassified	Unclassified	Unclassified	11	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	1
2. Keywords.....	1
3. Accomplishments.....	1
4. Impact.....	6
5. Changes/Problems.....	7
6. Products.....	7
7. Participants & Other Collaborating Organizations.....	8
8. Special Reporting Requirements.....	8
9. Appendices.....	8

1. INTRODUCTION

A main goal is to understand how protein kinase C epsilon (PKC ϵ) contributes to the progression of human prostate cancer. We and others have previously established that this kinase, which is a member of the novel family of protein kinase C (PKC) serine-threonine kinases, is up-regulated in prostate cancer. PKC ϵ is also overexpressed in several other epithelial cancers, such as lung, breast, and head and neck cancer, suggesting a potential association between the expression of this kinase and disease progression. This may be particularly true due to the fact that PKC ϵ activates mitogenesis and proliferation in many cell lines, including in prostate models. In addition, PKC ϵ has been implicated in cell motility, and previous studies from our laboratory in lung cancer cell lines identified this kinase as an upstream regulator of the small GTPase Rac, a GTP-binding protein that is known to promote actin cytoskeleton reorganization and cell motility. Therefore, based on these facts, we hypothesize that overexpression of PKC ϵ as observed in prostate cancer patients should be associated with disease progression, probably driving tumorigenesis and positively favoring the metastatic dissemination of prostate cancer cells.

Previous studies in our laboratory established that transgenic overexpression of PKC ϵ in the mouse prostate under the control of an androgen responsive promoter (probasin, PB) leads to the generation of preneoplastic lesions. These lesions were classified as hyperplasia and prostatic intraepithelial neoplasia (PINs), however we have not found any cancer lesions in these mice, even in aging mice. The PKC ϵ transgenic mice (also known as PB-PKC ϵ) was then crossed with mice haplodeficient for the tumor suppressor Pten, to generate the compound mice PB-PKC ϵ ;Pten^{+/-}. Notably, PB-PKC ϵ ;Pten^{+/-} mice developed prostatic adenocarcinomas that display elevated levels of phospho-Akt, phospho-mTOR, phospho-S6, phospho-Stat3, and phospho-NF- κ B. This signaling activation is consistent with the known role for PKC ϵ in the stimulation of pro-survival and pro-tumorigenic pathways. We found that some adenocarcinomas display invasive features, arguing for a potential role for PKC ϵ in metastasis. Thus, PKC ϵ cooperates with the loss of the tumor suppressor Pten, an alteration that occurs in a significant number of prostate cancer patients.

Using bioinformatics, we found that Pten-deficient prostate epithelial cells overexpressing PKC ϵ display elevated expression of the chemokine CXCL13, the ligand for the G-protein-coupled receptor CXCR5. This led us to hypothesize that PKC ϵ in conjunction Pten deficiency activate an autonomous autocrine loop that impacts on the growth and motile activity of prostate cancer cells. Based on these findings, our overall goal was to determine if the CXCL13: CXCR5 pathway contributes to prostate cancer progression. We speculate that Pten loss, which is one of the most common genetic alterations in human prostate cancer, cooperates with PKC ϵ to favor tumorigenesis and metastasis via the CXCL13: CXCR5 pathway. This novel signaling mechanism could be potentially targeted for therapeutic purposes in prostate cancer patients.

2. KEYWORDS

Prostate cancer, PKC ϵ , Pten, CXCL13, CXCR5, Akt, proliferation, migration, CXCL13 promoter, transcriptional activation, tumorigenesis, metastasis, autocrine loop, cell lines, mouse models.

3. ACCOMPLISHMENTS

a. What were the major goals of the project?

The Specific Aims proposed for this application were as follows:

- Aim 1: To establish the relevance of the CXCL13: CXCR5 axis *in vivo*.
- Aim 2: To determine the mechanisms behind the induction of CXCL13 by PKC ϵ .
- Aim 3: To establish the relevance of the PKC ϵ /Pten-CXCL13 association in human prostate tumors.

Main tasks for year 1 and 2 according to the SOW were as follows:

- To establish cellular models for inducible depletion of CXCL13 and CXCR5 in CaP-PKC ϵ cells (Months 1-8).

- To assess the effect of CXCL13 and CXCR5 inducible silencing on the tumorigenic activity of CaP-PKC ϵ cells (Months 3-8).
- To assess the effect of CXCL13 and CXCR5 inducible silencing on metastasis (Months 8-14).
- To determine if CXCL13 and CXCR5 are required for the formation of preneoplastic lesions in PB-PKC ϵ mice (Months 1-36).
- To establish the signaling pathways involved in PKC ϵ -induced release of CXCL13 from prostate cells (Months 14-20).
- To determine if PKC ϵ -mediated CXCL13 induction involves transcriptional activation of the CXCL13 promoter (Months 21-27).
- To determine the expression of PKC ϵ and Pten in human prostate tumors (Months 16-25)

b. What was accomplished under these goals?


During the second year of funding, we continued our work on the role of the CXCL13:CXCR5 axis in prostate cancer progression. We had previously generated prostate epithelial cell lines that overexpress PKC ϵ . However, as described in our previous annual report, these cell lines unexpectedly lost the expression of PKC ϵ , even if they were stable cell lines. As indicated last year, we had to construct again the PKC ϵ lentivirus and subsequently generate the corresponding cell lines, and this problem caused a significant delay in our research during the first year. Nevertheless, we solved this issue and successfully generated cell lines again.

In total we had 8 isogenic cell lines derived from parental P2 and P8 cells. Cell lines overexpressing PKC ϵ were named P2-PKC ϵ and P8-PKC ϵ . Pten-deficient cell lines (CaP2 and CaP8) overexpressing PKC ϵ were named CaP2-PKC ϵ and CaP8-PKC ϵ . For validation purposes, we confirmed again that Pten-deficient cell lines overexpressing PKC ϵ display the previously observed phenotype (enhanced motile activity and signaling, specifically Akt and Erk activation in response to growth factors).


Establishing a role for the CXCL13:CXCR5 axis in growth and tumorigenesis:

Since PKC ϵ overexpression and Pten loss individually and synergically promote the secretion of CXCL13 from prostate epithelial cells, and considering that CXCL13 or CXCR5 RNAi impairs the growth and motile capacity of CaP8-PKC ϵ cells in culture, we speculated that the phenotype driven by PKC ϵ *in vivo* is dependent on CXCL13 and CXCR5. Although the original plan involved the use of an inducible silencing approach, we decided to initiate the experiments using what we had proposed as an alternative approach, which was the use of non-inducible silencing by means of shRNA lentiviruses.


First, we infected P8, P8-PKC ϵ , CaP8, and CaP8-PKC ϵ cells with different shRNA lentiviruses for CXCR5, and selected with puromycin. As a control, we used a “non-target control” (NTC) shRNA lentivirus. We achieved significant silencing of CXCR5 in all for cell lines (Fig. 1).




CaP8-PKC ϵ cells, which display the highest growth rate in culture, significantly reduced their proliferative capacity upon CXCR5 RNAi depletion. A comparable inhibitory effect of CXCR5 RNAi was observed in cells overexpressing PKC ϵ (P8-PKC ϵ) or lacking Pten (CaP8) (Fig. 2).




We then assessed the effect of knocking down CXCR5 on the ability of cells to grow in soft agar. Consistent with experiments in liquid media, we found a significant reduction in the formation of colonies in soft agar in CaP8-PKC ϵ cells subject to CXCR5 RNAi (Fig. 3).



We carried out similar experiments in cells subject to CXCL13 depletion. We used shRNA lentivirus for CXCL13. We observed that stable silencing of CXCL13 expression impaired the ability of CaP8-PKC ϵ cells to grow in soft agar (Fig. 4).




In order to assess the effect of CXCR5 and CXCL13 depletion on the tumorigenic activity of CaP8-PKC ϵ cells, we used athymic nude mice. CaP8-PKC ϵ cells (parental, NTC, CXCL13 shRNA, and CXCR5 shRNA, using two different shRNAs in each case) were inoculated *s.c.* into ~8-week-old athymic male nude mice. Tumor growth was monitored for 35 days. As shown in Fig. 5, CaP8-PKC ϵ cells readily formed tumors in nude mice. However, when cells were infected with shRNA lentiviruses for either CXCL13 or CXCR5, tumor growth was markedly reduced. Therefore, the tumorigenic activity of CaP8-PKC ϵ cells is dependent upon the expression of CXCL13 and CXCR5, thus underscoring the requirement of an autocrine CXCR5-CXCL13 axis in growth and tumorigenic activity of these cells.




Establishing a role for the CXCL13:CXCR5 axis in signaling and metastasis:

Metastatic cells display highly motile and invasive phenotypes, and there is a known activation of the Rac pathway that correlates with motility and metastasis. Based on our preliminary data, PKC ϵ overexpression and Pten loss individually and synergically confer highly motile and invasive properties to prostate epithelial cells. Indeed, CaP8-PKC ϵ cells display a very high migratory capacity in Boyden chambers, both in the absence and presence of Matrigel. We hypothesize that the high motile/invasive/metastatic capacity of CaP8-PKC ϵ cells is mediated by the CXCL13:CXCR5 axis. We had previously showed that conditioned medium (CM) collected from prostate epithelial cells overexpressing PKC ϵ and/or Pten depleted confers a migratory response when added to naïve P8 cells. Indeed, we had indicated that the activity of the different CM varied as CM-CaP8-PKC ϵ > CM-P8-PKC ϵ ~ CM-CaP8 > CM-P8 cells, which was proportional to the CXCL13 production that we found in each cell line.


To determine if this pro-migratory effect is causally related to the released CXCL13, CaP8-PKC ϵ cells were subject to CXCL13 RNAi depletion, which as expected reduced CXCL13 mRNA levels (as determined by Q-PCR) and protein release (as determined by ELISA). Notably, CM from CXCL13-depleted CaP8-PKC ϵ cells lost its ability to induce a migratory response when added to naïve P8 cells. This effect was rescued by exogenous addition of CXCL13 (Fig. 6).




Similar results were observed when CM from CXCL13-depleted CaP8-PKC ϵ cells was added to either P8-PKC ϵ or CaP8 cells (Fig. 7).




Notably, when CXCR5 expression in the recipient naïve P8 cells was silenced, the pro-migratory activity of CM-CaP8-PKC ϵ was essentially lost (Fig. 8), further hinting at the important role of CXCL13.




To further establish if an autocrine CXCL13:CXCR5 loop mediates effects driven by PKC ϵ overexpression and Pten loss, we examined the effect of silencing either CXCL13 or CXCR5 on the migratory capacity of CaP8-PKC ϵ cells. Notably, in cells subject to CXCL13 RNAi the migratory activity of CaP8-PKC ϵ cells was essentially abolished (Fig. 9).



These results were validated using a neutralizing anti-murine CXCL13 antibody, which dose-dependently inhibited migration of CaP8-PKC ϵ cells compared to a non-specific isotype control antibody (Fig. 10).



In addition, when we silenced CXCR5 expression from PKC ϵ overexpressing and/or Pten-depleted cells, migratory activity was inhibited (Fig. 11). Thus, enhanced production of CXCL13 as a consequence of PKC ϵ overexpression and/or Pten loss plays a role in driving the migratory phenotype of CaP8-PKC ϵ cells. This also suggests that CXCL13 and CXCR5 may have an important role in metastatic dissemination.



Generation of PB-PKCε;CXCL13^{-/-} and PB-PKCε;CXCR5^{-/-} mice:

A main objective was to determine if CXCL13 and CXCR5 were required for the formation of preneoplastic lesions in PB-PKCε mice. We had previously reported that expression of PKCε in the mouse prostate confers preneoplastic lesions. Therefore, our goal was to generate mouse models of prostate-specific PKCε overexpression in CXCL13- or CXCR5-null backgrounds.

We ordered two mouse strains for CXCL13 and CXCR5 deficiency from the Jackson Laboratory: B6.129X1-Cxcl13^{tm1Cys/J} and B6.129S2(Cg)-Cxcr5^{tm1Lipp/J}, respectively. The CXCR5-deficient mice has been delivered and we are currently expanding the colony. Regarding the CXCL13-deficient mice, cryorecovery was needed, which delayed the shipping of the mice. This last strain recently arrived to the laboratory, and we are currently in the process of expanding and genotyping the mice.

Assessment of the role of PKCε in metastatic dissemination:

In our laboratory we were characterizing the role of PKCε in metastasis, particularly to the bone, which is a preferred site for metastasis of prostate cancer cells. We optimized a model for studying bone metastasis using PC3-ML cells, which we hope now to adapt to CaP8-PKCε cells. Importantly, we established that PKCε is required for the formation of bone metastatic foci, which was determined by silencing PKCε from PC3-ML cells. This model could also be adapted to assess the role for CXCL13 and CXCR5 in metastasis, which would help us to dissect the role of this pathway in the context of PKCε overexpression and Pten loss.

c. What opportunities for training and professional development has the project provided?

Nothing to report.

d. How were the results disseminated to communities of interest?

The P.I. presented results related to this project at several venues, as follows:

1. FASEB Summer Research Conference “Cell Signaling in Cancer: from mechanisms to therapy”, Steamboat Springs, CO. June 2016.
2. Universidad de La Plata, Argentina. June 2016.
3. University of Cambridge, Cambridge, UK. August 2016.
4. Tel Aviv University, Tel Aviv, Israel. August 2016
5. Cancer Spring Symposium from the Chilean Advanced Center for Chronic Diseases, Olmue, Chile. September 2016.

4. IMPACT

a. What was the impact on the development of the principal discipline(s) of the project?

Although CXCL13 has been primarily studied in the context of B cell migration, lymphoma, HIV and autoimmune diseases, emerging evidence indicates that this chemokine can be produced by prostate cancer cells. As we established that PKCε overexpression and Pten deficiency induce the expression of CXCL13 in prostate epithelial cells and prostate cancer cells produce significant levels of this chemokine, we believe that our studies can have significant impact not only in the understanding of the molecular basis of the disease but

also in therapeutics, as CXCR5 antagonists could be potentially inhibitors of prostate cancer cell growth and metastatic dissemination. It is also conceivable that CXCL13 could be used as a prognostic marker for prostate cancer progression.

b. What was the impact on other disciplines?

In the last years there were several studies suggesting potential roles for CXCL13 and its receptor CXCR5 in the progression of cancer, not only prostate cancer. For example, CXCL13 seems to have a role in breast and head and neck cancer. Therefore, our studies may reveal an important pathway that is regulated by PKC ϵ overexpression and Pten loss, which are alterations that also occur in other cancers, and this certainly can be translated into the development of novel therapeutic approaches for a broad number of malignancies. It is also important to notice that recent studies suggested potential roles for CXCL13 produced by the tumor microenvironment, thus our studies may be expanded to learn important novel signaling interactions that contribute to cancer progression through non-autonomous mechanisms.

c. What was the impact on technology transfer?

Nothing to report.

d. What was the impact on society beyond science and technology?

Nothing to report.

5. CHANGES/PROBLEMS

a. Changes in approach and reasons for change

As described in our first annual report, we had found unexpected issues in the maintenance of the stable expression of PKC ϵ in CaP8-PKC ϵ cells. It took a while to solve this problem, and due to the delay that this caused we estimate that it would be very hard to complete all the proposed work in the estimated time-frame for this proposal (3 years). Therefore, our goal now is to focus our experimental efforts and allocate resources to address key questions in the remaining time for this grant. Hopefully this approach will provide us significant information on fundamental questions that should address the potential role of the CXCL13:CXCR5 pathway in prostate cancer progression, particularly tumorigenesis and aspects of the metastatic cascade, such as migration. One approach to save time was the use of traditional RNAi approaches rather than inducible, as this last methodology is more laborious, expensive, and time-consuming. Indeed, we achieved great success with non-inducible RNAi and were able to address very important experimental questions. Due to the long-term nature of some of our proposed experiments, such as studies involving animal crossings, metastasis in mice and human specimens, we hope to focus primarily on short-term questions, such as those involving the analysis of signaling mechanisms.

b. Actual or anticipated problems or delays and actions or plans to resolve them

This has been explained above.

c. Changes that had a significant impact on expenditures

No significant changes.

d. Significant changes in use or care of human subjects, vertebrates, biohazards, and/or select agents.

Nothing to report.

6. PRODUCTS

Gutierrez-Uzquiza, A., Lopez-Haber, C., Jernigan, D.L., Fatatis, A., Kazanietz, M.G. PKC ϵ is an essential mediator of prostate cancer bone metastasis. Mol Cancer Res. 13:1336-1346 (2015).

7. PARTICIPANTS AND OTHER COLLABORATING ORGANIZATIONS

a. What individuals have worked on the project?

There are no changes with regards to personnel. Personnel includes Marcelo G. Kazanietz (P.I.), Michael Feldman (Co-investigator), Rachana Garg (Research Associate), and Cynthia Lopez-Haber (Technician).

b. Has there been a change in the active other support of the PD/PI(s) or senior key personnel since the last reporting period?

The P.I. has been awarded a new R01 project during the last year:
R01 CA196232 (P.I. Kazanietz), NCI, NIH (01/16-12/20)

“Effectors of protein kinase C-mediated tumor progression”. The main goal in this proposal is to characterize COX-2 and mPGES-1 as PKC effectors in prostate cancer, using cellular and animal models. Pharmacological and inducible shRNA approaches will be used to determine if COX-2 is required for the tumorigenicity of PKC ϵ overexpressing/Pten depleted prostate epithelial cells. The role of individual p110 PI3Ks in COX-2/mPGES-1/PGF2 induction will be studied. There is no overlap with current proposal.

c. What other organizations were involved as partners?

Nothing to report.

8. SPECIAL REPORTING REQUIREMENTS

Not applicable.

9. APPENDICES

Not applicable.